Cas:886363-26-4 2-[4-(3,5-difluorophenyl)phenyl]acetic acid manufacturer & supplier

Chemical Name:2-[4-(3,5-difluorophenyl)phenyl]acetic acid

CAS.NO:886363-26-4

Synonyms:2-(3′,5′-Difluoro-[1,1′-biphenyl]-4-yl)acetic acid;4-(3,5-Difluorophenyl)phenylacetic acid;4-biphenyl-3′,5′-difluoro-acetic acid;(3′,5′-difluoro-biphenyl-4-yl)-acetic acid

Molecular Formula:C₁₄H₁₀F₂O₂

Molecular Weight:248.22500

HS Code:2916399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:385.4ºC at 760 mmHg

Density:1.302g/cm3

Index of Refraction:1.563

PSA:37.30000

Exact Mass:248.06500

LogP:3.25890

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-(3′,5′-Difluoro-[1,1′-biphenyl]-4-yl)acetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(3′,5′-difluoro-biphenyl-4-yl)-acetic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-biphenyl-3′,5′-difluoro-acetic acid Use and application,4-(3,5-Difluorophenyl)phenylacetic acid technical grade,usp/ep/jp grade.

Related News: Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm. 2-[4-(3,5-difluorophenyl)phenyl]acetic acid manufacturer Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology. 2-[4-(3,5-difluorophenyl)phenyl]acetic acid supplier Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. 2-[4-(3,5-difluorophenyl)phenyl]acetic acid vendor Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. 2-[4-(3,5-difluorophenyl)phenyl]acetic acid factory Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.